Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2- (phosphonomethoxy)ethyl]adenine in vitro

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 9, 1996, Pages 2212-2216

  Cherrington, J M ^a   Mulato, A S ^a   Fuller, M D ^a   Chen, M S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYCYTIDINE DERIVATIVE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE DERIVATIVE; 9 [2,5 DIHYDRO 5 (PHOSPHONOMETHOXY) 2 FURANYL]ADENINE; ACYCLIC NUCLEOSIDE; ADEFOVIR; DIDANOSINE; FOSCARNET; LAMIVUDINE; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RETROVIRUS INFECTION; SEQUENCE ANALYSIS; VIROGENESIS; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 0029795423     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.9.2212     Document Type: Article

References (32)

1. Boyer, P. L., A. L. Ferris, and S. H. Hughes. 1992. Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1. J. Virol. 66:1031-1039.
2. De Clercq, E., A. Holy, I. Rosenberg, T. Sakuma, J. Balzarini, and P. C. Maudgal. 1986. A novel selective broad-spectrum anti-DNA virus agent. Nature (London) 323:464-467.
3. De Clercq, E., T. Sakuma, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, and A. Holy. 1987. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antivir. Res. 8:261-272.
4. Fitzgibbon, J. E., R. M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
5. Foli, A., K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, X. Gu, J. M. Cherrington, H. Mitsuya, and R. Yarchoan. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antivir. Res., in press.
6. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
7. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19.
8. Gu, Z., E. J. Arts, M. A. Parniak, and M. A. Wainberg. 1994. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′-triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92:2760-2764.
9. Gu, Z., R. S. Fletcher, E. J. Arts, M. A. Wainberg, and M. A. Parniak. 1994. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2′, 3′-dideoxycytidine, 2′, 3′-dideoxy-3′-thiacytidine, and 2′,3′-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro. J. Biol. Chem. 269:28118-28122.
10. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
11. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
12. Gu, Z., H. Salomon, J. M. Cherrington, A. S. Mulato, M. S. Chen, R. Yarchoan, A. Foli, K. Sogocio, and M. A. Wainberg. 1995. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 39:1888-1891.
13. Holy, A., and K. Rosenberg. 1987. Synthesis of 9-(2-phosphonomethoxyethyl)adenine and related compounds. Collect. Czech. Chem. Commun. 52: 2801-2809.
14. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, A. Hizi, S. H. Hughes, and E. Arnold. 1993. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA 90:6320-6324.
15. Kellam, P., C. A. B. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
16. Kim, C. U., B. Y. Luh, and J. C. Martin. 1991. Regiospecific and highly stereoselective electrophilic addition of furanoid glycols: synthesis of phosphonate nucleotide analogues with potent activity against HIV. J. Org. Chem. 56:2642-2647.
17. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure of 3.5A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
18. Lacey, S. F., and B. A. Larder. 1994. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture. Antimicrob. Agents Chemother. 38:1428-1432.
19. Larder, B. A., K. E. Coates, and S. D. Kemp. 1991. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65:5232-5236.
20. Larder, B. A., A. G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
21. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
22. Pauwels, R., J. Balzarini, D. Schols, M. Baba, J. Desmyter, I. Rosenberg, A. Holy, and E. De Clercq. 1988. Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32:1025-1030.
23. Rooke, R., M. Tremblay, H. Soudeyns, L. DeStephano, X.-J. Yao, M. Fanning, J. S. G. Montaner, M. O'Shaughnessy, K. Gelmon, C. Tsoukas, H. Ruedy, and M. A. Wainberg. 1989. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine (AZT) therapy. AIDS 3:411-415.
24. Schinazi, R. F., R. J. Lloyd, M. H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
25. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
26. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
27. Vasudevachari, M. B., C. Battista, H. C. Lane, and N. P. Salzman. Unpublished data.
28. Wainberg, M. A., H. Salomon, Z. Gu, J. S. G. Montaner, T. P. Cooley, R. McCaffrey, J. Ruedy, H. M. Hirst, N. Cammack, J. Cameron, and W. Nicholson. 1995. Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9:351-357.
29. Walker, R. E., S. E. Vogel, H. S. Jaffe, M. A. Polis, J. A. Kovaks, J. Falloon, R. T. Davey, O. Ebeling, K. Cundy, D. Paar, N. Markowitz, H. Masur, and H. C. Lane. 1993. A phase I/II study of PMEA in HIV infected patients, abstr. 522, p. 148. In Program and abstracts of the First National Conference on Human Retroviruses and Related Infections. American Society for Microbiology, Washington, D.C.
30. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, K. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effect: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
31. Wu, J., E. Amandoron, X. Li, M. A. Wainberg, and M. A. Parniak. 1994. Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. J. Biol. Chem. 268:9980-9985.
32. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R, T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.